688506 百利天恒
已收盘 08-25 15:00:00
资讯
新帖
简况
百利天恒最新公告：宜泽康®乳腺癌III期临床达主要终点
证券之星 · 18:57
百利天恒最新公告：宜泽康®乳腺癌III期临床达主要终点
百利天恒：宜泽康现有产能可充分满足现阶段国内商业化与国内外临床需求
证券之星 · 08-24 15:36
百利天恒：宜泽康现有产能可充分满足现阶段国内商业化与国内外临床需求
每周股票复盘：百利天恒（688506）BL-B01D1期中分析达主要终点
证券之星 · 08-23 01:42
每周股票复盘：百利天恒（688506）BL-B01D1期中分析达主要终点
百利天恒依据首例给药临床试验确认17亿元里程碑收入，BMS尚未打款缺少实质性临床终点数据
市场资讯 · 08-21
百利天恒依据首例给药临床试验确认17亿元里程碑收入，BMS尚未打款缺少实质性临床终点数据
百利天恒最新公告：双抗ADC肺癌III期临床达主要终点
证券之星 · 08-17
百利天恒最新公告：双抗ADC肺癌III期临床达主要终点
从BD高光到亏损回归，百利天恒面临什么考题？
蓝鲸财经 · 08-10
从BD高光到亏损回归，百利天恒面临什么考题？
蓝鲸：百利天恒4递表港股 去年"刹车"或因市场环境错配
中金财经 · 08-10
蓝鲸：百利天恒4递表港股 去年"刹车"或因市场环境错配
每周股票复盘：百利天恒（688506）递交H股上市申请
证券之星 · 08-09
每周股票复盘：百利天恒（688506）递交H股上市申请
百利天恒四闯港交所，冲刺四川首家A+H创新药企业
金融投资网 · 08-07
百利天恒四闯港交所，冲刺四川首家A+H创新药企业
【新股IPO】百利天恒向港交所主板递交上市申请 拟实现A+H上市
金吾财讯 · 08-06
【新股IPO】百利天恒向港交所主板递交上市申请 拟实现A+H上市
百利天恒再度递表港交所 此前上市前夕主动刹车
贝壳财经 · 08-06
百利天恒再度递表港交所 此前上市前夕主动刹车
百利天恒重启港股上市：第一季净亏7.8亿 去年配售37亿 市值1247亿
雷递网 · 08-06
百利天恒重启港股上市：第一季净亏7.8亿 去年配售37亿 市值1247亿
百利天恒最新公告：向香港联交所递交H股发行上市申请
证券之星 · 08-06
百利天恒最新公告：向香港联交所递交H股发行上市申请
四川百利天恒药业股份有限公司向港交所提交上市申请书
南方财经网 · 08-06
四川百利天恒药业股份有限公司向港交所提交上市申请书
百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药
第一财经 · 08-06
百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药
每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床
证券之星 · 08-02
每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床
研报掘金丨东北证券：首予百利天恒“增持”评级，核心产品III期临床全面铺开
格隆汇 · 07-31
研报掘金丨东北证券：首予百利天恒“增持”评级，核心产品III期临床全面铺开
百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准
证券之星 · 07-30
百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准
百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组
格隆汇 · 07-26
百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组
百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组
智通财经 · 07-26
百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是创新生物药业务、化药制剂、中成药制剂。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":264.04,"timestamp":1787641200000,"preClose":264.98,"halted":0,"volume":1418085,"delay":0,"changeRate":-0.0035,"floatShares":413000000,"shares":413000000,"eps":-3.1408,"marketStatus":"已收盘","change":-0.94,"latestTime":"08-25 15:00:00","open":266.67,"high":266.67,"low":259.47,"amount":373000000,"amplitude":0.0272,"askPrice":264.04,"askSize":0,"bidPrice":264.02,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-3.1408,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":5,"adr":0,"adjPreClose":264.98,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787621400000,1787628600000],[1787634000000,1787641200000]],"highLimit":291.48,"lowLimit":238.48,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":19.32,"roa":"--","roe":"--","epsLYR":-2.61,"committee":0.285714,"marketValue":109015000000,"turnoverRate":0.0034,"status":1,"afterMarket":{"amount":52808,"volume":200,"close":264.04,"buyVolume":0,"sellVolume":1386,"time":1787643237746,"indexStatus":"已收盘 08-25 15:30:00","preClose":264.98},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1787644800000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":109015000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2662736497","title":"百利天恒最新公告：宜泽康®乳腺癌III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736497?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655433,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的全球首创双抗ADC宜泽康(伦康依隆妥单抗)用于局部晚期、复发或转移性HR+HER2-乳腺癌的III期临床试验，在预设期中分析中达到无进展生存期(PFS)主要终点。这是该药第5个达主要终点的III期研究，也是全球首个双抗ADC在HR+HER2-乳腺癌治疗中达主要终点。目前，该药已有2项适应症获NMPA上市批准，1项NDA获CDE受理。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229322","title":"百利天恒：宜泽康现有产能可充分满足现阶段国内商业化与国内外临床需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661229322?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:36","pubTimestamp":1787556990,"startTime":"0","endTime":"0","summary":"证券之星消息，百利天恒08月24日在投资者关系平台上答复投资者关心的问题。宜泽康国内销售单价目前确定了吗？宜泽康作为公司自主研发的全球首款双抗ADC药物，现有产能可充分满足现阶段国内商业化与国内外临床需求，公司将结合后续市场情况做好产能保障。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400015457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661116252","title":"每周股票复盘：百利天恒（688506）BL-B01D1期中分析达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2661116252","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661116252?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:42","pubTimestamp":1787420532,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，百利天恒报收于282.71元，较上周的302.0元下跌6.39%。本周，百利天恒8月17日盘中最高价报307.8元。百利天恒当前最新总市值1167.24亿元，在化学制药板块市值排名3/149，在两市A股市值排名165/5210。目前该药已获NMPA批准用于鼻咽癌和食管鳞癌，三阴乳腺癌上市申请已获受理。公司已开展40余项临床试验，含20项III期研究，多项适应症获CDE突破性治疗认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661325043","title":"百利天恒依据首例给药临床试验确认17亿元里程碑收入，BMS尚未打款缺少实质性临床终点数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2661325043","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661325043?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:08","pubTimestamp":1787296080,"startTime":"0","endTime":"0","summary":"百利天恒，于2023年1月登陆上交所科创板。即使抛开上述的勾稽关系断裂不谈，该笔17.76亿元里程碑收入的确认时点同样令人费解，或涉嫌利用会计估计的自由裁量权提前确认收入以粉饰报表，或误导投资者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-21/doc-inipaenp6496930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MDTX","BMS","688506","PSYK","91194","IBBJ","BK0239","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489990","title":"百利天恒最新公告：双抗ADC肺癌III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489990","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660489990?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:57","pubTimestamp":1786960645,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的伦康依隆妥单抗用于EGFR敏感突变非小细胞肺癌的III期试验期中分析达PFS主要终点，OS有获益趋势。该药为全球首个且唯一获批上市的EGFR×HER3双抗ADC，已有4项III期研究达主要终点。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700024301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986658","title":"从BD高光到亏损回归，百利天恒面临什么考题？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986658","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658986658?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:49","pubTimestamp":1786348144,"startTime":"0","endTime":"0","summary":"相对于坎坷的赴港闯关之路，在生物科技这条赛道上，百利天恒已有产品实现商业化。从项目成熟度看，百利天恒并非停留在“早期研发概念验证”阶段。盈利高峰来自授权兑现，亏损继续扩大百利天恒最容易抓住眼球的，是其利润表在近两年出现过明显波动。这组数据本身已经足够说明，百利天恒并不是一家已经进入稳定盈利通道的创新药企业。从这个角度看，百利天恒的长板与短板都很鲜明。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786328428501757201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BD","91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658213604","title":"蓝鲸：百利天恒4递表港股 去年\"刹车\"或因市场环境错配","url":"https://stock-news.laohu8.com/highlight/detail?id=2658213604","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658213604?lang=zh_cn&edition=full","pubTime":"2026-08-10 11:47","pubTimestamp":1786333624,"startTime":"0","endTime":"0","summary":"中国经济网北京8月10日讯 蓝鲸新闻8月7日发布报道《百利天恒四度递表港交所，去年IPO临门一脚“刹车”后再闯关》。有业内人士分析，彼时百利天恒延迟H股上市的核心原因是其定价策略与市场环境错配有关。百利天恒截至2026年8月6日的收盘价已经来到301.97元/股，甚至低于相对于去年11月10日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260810/32330109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4585","BK0239","IPOS","91194","KCAI","VXUS","688506","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658467316","title":"每周股票复盘：百利天恒（688506）递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2658467316","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658467316?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:35","pubTimestamp":1786210512,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，百利天恒报收于307.07元，较上周的298.0元上涨3.04%。本周，百利天恒8月7日盘中最高价报312.0元。百利天恒当前最新总市值1267.81亿元，在化学制药板块市值排名3/149，在两市A股市值排名151/5205。本周关注点公司公告汇总：百利天恒已向港交所递交H股发行上市申请。公司公告汇总：BL-M14D1联合免疫治疗全球III期临床完成首例给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657690454","title":"百利天恒四闯港交所，冲刺四川首家A+H创新药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2657690454","media":"金融投资网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657690454?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:54","pubTimestamp":1786085641,"startTime":"0","endTime":"0","summary":"金融投资报记者刘庆华8月6日晚间，科创板上市川企百利天恒(688506)发布公告称，公司已于当日正式向港交所主板提交H股发行上市申报材料，开启第四次港股上市冲刺。这已是百利天恒第四次闯关港交所。不同于前三次递交材料时管线仅停留在临床阶段的窘境，今年6月，企业核心自研双抗ADC药物宜泽康成功获批并启动全国商业化推广，成为本次闯关最核心的底气支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835147692.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835147692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","MEDX","BK0239","159992","91194","688506","BK1574","IBBQ","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657539286","title":"【新股IPO】百利天恒向港交所主板递交上市申请 拟实现A+H上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657539286","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657539286?lang=zh_cn&edition=full","pubTime":"2026-08-06 23:15","pubTimestamp":1786029314,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所2026年8月6日文件披露，四川百利天恒药业股份有限公司向港交所主板递交上市申请，拟实现A+H两地上市，联席保荐人为中信证券、杰富瑞、中金公司、德意志银行。核心产品宜泽康是全球首款获批双特异性ADC，已于2026年6月及7月拿下鼻咽癌、食管鳞癌两项适应症上市批件。截至2026年3月31日止三个月的期末现金及现金等价物达29.30亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NGRkYjNjMjA4MTA4NTEzNjUxMTI4.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NGRkYjNjMjA4MTA4NTEzNjUxMTI4.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987668","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","FRHC","HEXmain","KCE","BK0239","REDS","91194","IPOS","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657865840","title":"百利天恒再度递表港交所 此前上市前夕主动刹车","url":"https://stock-news.laohu8.com/highlight/detail?id=2657865840","media":"贝壳财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657865840?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:15","pubTimestamp":1786025700,"startTime":"0","endTime":"0","summary":"公司已于当日向香港联交所递交了本次发行的申请，并于同日在香港联交所网站刊登了本次发行的申请资料。百利天恒表示，该申请资料为公司按照香港证券及期货事务监察委员会及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新和变动。百利天恒为一家创新药企业。百利天恒于2023年1月登陆上交所科创板，登陆A股时，公司尚未实现盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-06/doc-inimkwtf0537020.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-06/doc-inimkwtf0537020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91194","HEXmain","BK0239","688506","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657023639","title":"百利天恒重启港股上市：第一季净亏7.8亿 去年配售37亿 市值1247亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2657023639","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657023639?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:20","pubTimestamp":1786018817,"startTime":"0","endTime":"0","summary":"四川百利天恒药业股份有限公司日前重启IPO，并更新招股书，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260806/6392164439947598114497040.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260806/6392164439947598114497040.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34571/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688506","BK4585","KCAI","IPOS","91194","BK0239","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657202639","title":"百利天恒最新公告：向香港联交所递交H股发行上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657202639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657202639?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:19","pubTimestamp":1786018792,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司已于2026年8月6日向香港联交所递交境外上市外资股(H股)发行并上市的申请，并于同日在香港联交所网站刊登申请资料。该申请尚需取得证监会、香港证监会及香港联交所等监管机构的批准、核准或备案，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600036460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657393636","title":"四川百利天恒药业股份有限公司向港交所提交上市申请书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657393636","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657393636?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:48","pubTimestamp":1786016880,"startTime":"0","endTime":"0","summary":"南方财经8月6日电，利弗莫尔证券显示，四川百利天恒药业股份有限公司向港交所提交上市申请书，联席保荐人为中信证券、Jefferies、中金公司、德意志银行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063834046061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063834046061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657681894","title":"百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2657681894","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657681894?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:22","pubTimestamp":1786008136,"startTime":"0","endTime":"0","summary":"【百利天恒：创新药治疗一线广泛期小细胞肺癌全球多中心III期临床试验完成首例受试者给药】百利天恒公告，公司自主研发的创新生物药BL-M14D1联合PD-L1单抗对比含铂化疗联合PD-L1单抗治疗一线广泛期小细胞肺癌的全球多中心III期临床试验已于近日完成首例受试者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063833940921.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063833940921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","688506","BK1161","IBBQ","91194","159992","MDTX","BMED","MEDX","III","PSYK","06978","IBBJ","BK4134","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656316804","title":"每周股票复盘：百利天恒（688506）HER2 ADC进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656316804?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:29","pubTimestamp":1785605350,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，百利天恒报收于298.0元，较上周的311.0元下跌4.18%。本周关注点来自公司公告汇总：注射用T-Bren在胆道癌III期临床完成首例受试者入组来自公司公告汇总：注射用BL-B01D1获准开展晚期实体瘤临床试验公司公告汇总四川百利天恒药业股份有限公司自主研发的注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中开展的III期随机对照临床试验已完成首例受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","02615","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655268358","title":"研报掘金丨东北证券：首予百利天恒“增持”评级，核心产品III期临床全面铺开","url":"https://stock-news.laohu8.com/highlight/detail?id=2655268358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655268358?lang=zh_cn&edition=full","pubTime":"2026-07-31 15:14","pubTimestamp":1785482064,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0276","BK0183","BK0239","BK0188","688506","000686"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655873611","title":"百利天恒最新公告：注射用BL-B01D1（皮下注射）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655873611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655873611?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:19","pubTimestamp":1785406775,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药监局签发的《药物临床试验批准通知书》，自主研发的创新生物药注射用BL-B01D1(皮下注射)获批在晚期实体瘤患者中开展临床试验。注射用BL-B01D1（皮下注射）是在公司伦康依隆妥单抗/宜泽康（BLB01D1/iza-bren）的基础上开发的皮下制剂，有望缩短临床给药时长，提高给药便捷性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000029541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654063189","title":"百利天恒：注射用T-Bren治疗胆道癌III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654063189","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654063189?lang=zh_cn&edition=full","pubTime":"2026-07-26 15:59","pubTimestamp":1785052768,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02615","BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654639210","title":"百利天恒(688506.SH)：注射用T-Bren(HER2 ADC)临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2654639210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654639210?lang=zh_cn&edition=full","pubTime":"2026-07-26 15:48","pubTimestamp":1785052138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司自主研发的创新生物药注射用T-Bren在HER2表达的经含铂化疗治疗失败的局部晚期或转移性胆道癌患者中对比T-Bren与医生选择的化疗的III期随机对照临床试验已于近日完成首例受试者入组。据悉，T-Bren是一种靶向HER2的创新型ADC，具有同类最佳潜力，已在临床试验中展示出显著的抗肿瘤功效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02615","688506","BMED","BK4231","BK4080","91194","NETL","BK0239","MDTX","IBBQ","IBBJ","PSYK","ADC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787668701731,"stockEarnings":[{"period":"1week","weight":-0.115},{"period":"1month","weight":-0.148},{"period":"3month","weight":0.1181},{"period":"6month","weight":-0.0506},{"period":"1year","weight":-0.2012},{"period":"ytd","weight":-0.1799}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0178},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.064},{"period":"1year","weight":0.0147},{"period":"ytd","weight":-0.0219}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7777人(较上一季度增加34.99%)","perCapita":"53089股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是创新生物药业务、化药制剂、中成药制剂。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}